Altobaishat Obieda, Abouzid Mohamed, Tanashat Mohammad, Amin Ahmed Mazen, Turkmani Mustafa, Abuelazm Mohamed
Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Department of Physical Pharmacy and Pharmacokinetics, Faculty of Pharmacy, Poznan University of Medical Sciences, Poznan, Poland.
Future Cardiol. 2024 Dec-Dec;20(15-16):859-870. doi: 10.1080/14796678.2024.2440220. Epub 2024 Dec 12.
Rotational atherectomy (RA) has been proven to treat coronary artery calcification (CAC) during percutaneous coronary intervention (PCI).
This study evaluates the safety and efficacy of RA followed by cutting balloon angioplasty (ROTACUT) before stent placement in CAC.
A systematic review and meta-analysis of randomized controlled trials and observational studies was conducted. PubMed, Web of Science, Scopus, and Cochrane were searched through January 2024. We used Stata version 17 to pool dichotomous data using risk ratio (RR) and continuous data using mean difference (MD), with a 95% confidence interval (CI).
Eight studies with 846 patients were included. There was no significant difference between ROTACUT and RA + bare balloons in major adverse cardiovascular events (MACE) (RR:0.60; 95%CI [0.31,1.16], = 0.13), cardiac death (RR:1.32; 95%CI [0.42,4.14], = 0.64), target vessel revascularization (TVR) (RR:1.89; 95%CI [0.40,8.84], = 0.42), target lesion revascularization (TLR) (RR:0.83; 95%CI [0.39,1.79], = 0.64), procedural duration (MD:0.78; 95%CI [-4.68,6.24], = 0.78), stent thrombosis (RR:0.81; 95%CI [0.22,2.95], = 0.75), and any procedure-related complications (RR:0.86; 95%CI [0.42,1.75], = 0.68).
ROTACUT and RA + bare balloons demonstrated similar efficacy and safety profiles regarding MACE, cardiac death, TVR, TLR, procedural duration, stent thrombosis, and all safety outcomes.
在经皮冠状动脉介入治疗(PCI)期间,旋磨术(RA)已被证实可用于治疗冠状动脉钙化(CAC)。
本研究评估在支架置入前,旋磨术联合切割球囊血管成形术(ROTACUT)治疗冠状动脉钙化的安全性和有效性。
对随机对照试验和观察性研究进行系统评价和荟萃分析。检索截至2024年1月的PubMed、Web of Science、Scopus和Cochrane数据库。我们使用Stata 17版本,采用风险比(RR)汇总二分数据,采用均值差(MD)汇总连续数据,并给出95%置信区间(CI)。
纳入8项研究,共846例患者。在主要不良心血管事件(MACE)(RR:0.60;95%CI[0.31,1.16],P = 0.13)、心源性死亡(RR:1.32;95%CI[0.42,4.14],P = 0.64)、靶血管血运重建(TVR)(RR:1.89;95%CI[0.40,8.84],P = 0.42)、靶病变血运重建(TLR)(RR:0.83;95%CI[0.39,1.79],P = 0.64)、手术时长(MD:0.78;95%CI[-4.68,6.24],P = 0.78)、支架血栓形成(RR:0.81;95%CI[0.22,2.95],P = 0.75)以及任何与手术相关的并发症(RR:0.86;95%CI[0.42,1.75],P = 0.68)方面,ROTACUT与RA联合普通球囊之间无显著差异。
在MACE、心源性死亡、TVR、TLR、手术时长、支架血栓形成以及所有安全性结局方面,ROTACUT与RA联合普通球囊显示出相似的疗效和安全性。